studies suggest that alternative splicing of genes is associated with complex diseases including AUD, identification of specific splicing events would provide not only stronger evidence that RNA alternative splicing impacts risk for AUD, but also the molecular basis for experimentally verifying the causal nature of RNA alternative splicing. To identify these splicing events, it is necessary to quantify the proportion of splicing outcome that is genetically determined and evaluate the contribution of this proportion to AUD risk.
